<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164069</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-19067</org_study_id>
    <secondary_id>NCI-2019-04723</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT04164069</nct_id>
  </id_info>
  <brief_title>Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab</brief_title>
  <official_title>A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Chemotherapy and Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Noonan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib trial studies side effects and best dose of dasatinib in preventing
      oxaliplatin-induced peripheral neuropathy in patients with stage IV colorectal cancer who are
      receiving FOLFOX regimen and bevacizumab. Drugs used in chemotherapy, such as leucovorin,
      fluorouracil, and oxaliplatin (FOLFOX regimen), work in different ways to stop the growth of
      tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
      from spreading. However, the buildup of oxaliplatin in the cranial nerves can result in
      damage or the nerves. Dasatinib may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Blocking these enzymes may reduce oxaliplatin-induced
      peripheral neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the recommended phase 2 dose (RP2D) of dasatinib in combination with
      oxaliplatin and fluorouracil (5FU) (modified version 6 regimen of leucovorin, fluorouracil
      and oxaliplatin [mFOLFOX6]) with or without bevacizumab in patients with metastatic
      colorectal cancer, defined as the lowest intermittent dose of dasatinib that affects serum
      biomarkers of OCT2 without influencing the pharmacokinetic properties of oxaliplatin.

      II. To determine the toxicity profile (based on Chemotherapy-Induced Peripheral Neuropathy
      [CIPN]20 and Common Terminology Criteria for Adverse Events [CTCAE] version [v.] 5.0) of
      dasatinib in combination with oxaliplatin/5-FU/bevacizumab in patients with colorectal
      cancer.

      SECONDARY OBJECTIVES:

      I. To evaluate the influence of dasatinib on the pharmacokinetics of oxaliplatin and vice
      versa in these patients.

      OUTLINE: This is a dose-escalation study of dasatinib.

      Patients receive oxaliplatin intravenously (IV) over 2 hours, leucovorin IV over 2 hours,
      fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on
      days 1 and 15. Patients also receive dasatinib orally (PO) once daily (QD) on days 14, 15,
      and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes
      on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of
      disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    PI Decision
  </why_stopped>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose (RP2D) of dasatinib</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>The RP2D will be defined as the lowest intermittent dose of dasatinib that affects serum biomarkers of OCT2 without influencing the pharmacokinetic properties of oxaliplatin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>At the end of Cycle 1 (cycle length is 28 days)</time_frame>
    <description>The dose-limiting toxicity and toxicity profile will be based using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and Chemotherapy-Induced Peripheral Neuropathy (CIPN) 20. Toxicity will be defined as adverse events deemed to be at least possibly related to dasatinib treatment. Adverse events and toxicities will be summarized by dose level, and will tabulate these events by type and severity. Will summarize the numbers of patients who required dose reductions in dasatinib or oxaliplatin and the cumulative doses received. The CIPN20 will be measured in these subjects, and will be summarized within and across dose levels, and will be used to support and inform assumptions for a subsequent phase 2 trial.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Dasatinib on pharmacokinetics (PK) of oxaliplatin</measure>
    <time_frame>Baseline, days 1, 2, and 14</time_frame>
    <description>Objective is to evaluate the influence of dasatinib on the pharmacokinetics of oxaliplatin and vice versa. Oxaliplatin PK will be measured at pre-dose, 1 hour, immediately prior to end of infusion of oxaliplatin, and 0.5, 1, 2, 4, and 24 hours after end of infusion on day 1; Dasatinib PK will be measured at pre-dose and 0.5, 1.5, 2.5, 3, 4.5, and 6.5 hours after taking dasatinib on day 14; PK of dasatinib and oxaliplatin will be measured on day 15 pre-dose of dasatinib, prior to starting oxaliplatin infusion, 1 hour after start of oxaliplatin infusion, immediately prior to end of infusion with oxaliplatin, and at 0.5, 1, 2, 4, and 24 hours after end of oxaliplatin infusion. PK parameters calculated using standard non-compartmental methods, and non-linear mixed effect models will be created to inform the use of limited-sampling strategies for subsequent confirmatory studies. Area Under the Curve [AUC] will be calculated for each drug Oxaliplatin - ug x h/ml and Dasatinib- ng x h/ml</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Colorectal Carcinoma</condition>
  <condition>Metastatic Colorectal Carcinoma</condition>
  <condition>Stage IV Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Dasatinib Hydrate</other_name>
    <other_name>Dasatinib Monohydrate</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>5 Fluorouracil</other_name>
    <other_name>5 Fluorouracilum</other_name>
    <other_name>5 FU</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>5FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>citrovorum factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Prevention (dasatinib, mFOLFOX, bevacizumab)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed stage IV (advanced/metastatic) colorectal cancer who are candidates for
             mFOLFOX6, with or without bevacizumab therapy. Pathological confirmation of colorectal
             cancer is required. Patients may have had prior therapy for metastatic colorectal
             cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Platelets &gt;= 100 x 10^9/L

          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 x upper limit of
             normal (ULN) unless subject is receiving anticoagulant therapy as long as PT or
             partial thromboplastin time (PTT) is within therapeutic range of intended use of
             anticoagulants

          -  Activated partial thromboplastin time (aPTT) =&lt; 1.5 x ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
             of anticoagulants

          -  Serum creatinine: =&lt; 1.5 x upper limit of normal (ULN), or measured or calculated
             creatinine clearance (estimated by Cockcroft-Gault formula or measured ) &gt;= 50 mL/min
             urine protein:creatinine (UPC) &lt; 2

          -  Total bilirubin =&lt; 2 x ULN

          -  Aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             ULN, unless evidence of liver metastases, then AST/alanine aminotransferase (ALT) =&lt; 5
             x ULN

          -  Blood pressure (if receiving bevacizumab): systolic blood pressure (SBP) &gt; 150 or
             diastolic blood pressure (DBP) &gt; 100

          -  Serum potassium and magnesium within the institution normal range. Before starting
             therapy with dasatinib, hypokalemia and hypomagnesemia will be corrected to potassium
             &gt;= 4.0 mmol/L, magnesium &gt;= 2.0 mg/dL-supplementation is allowed

          -  Corrected QT (QTc) interval =&lt; 440 mSec

          -  Women of child-bearing potential must agree to use adequate contraception prior to
             study entry, for the duration of study participation and for 3 months after completion
             of study treatment administration

          -  Prior chemotherapy in the adjuvant (no prior exposure of oxaliplatin) or metastatic
             setting is allowed

        Exclusion Criteria:

          -  Prior exposure to any type of neurotoxic chemotherapy

          -  Pre-existing neuropathy of any type or grade

          -  Treatment with any other investigational agents within 4 weeks or 5 half-lives
             (whichever is longer) prior to the first dose of dasatinib

          -  Gastrointestinal (GI) disease or impairment of GI function that is likely to
             significantly alter the absorption of dasatinib

          -  Use of potent OCT2 and/or CYP3A4 inhibitors if treatment cannot be either safely
             discontinued or switched to a different medication prior to starting dasatinib

          -  Concurrent cetuximab or panitumumab

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, known human immunodeficiency virus (HIV) diagnosis if receiving combination
             antiretroviral therapy, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations, including
             psychotic disorders, dementia and substance use disorders, that would limit compliance
             with study requirements

          -  Because there is an unknown potential risk for adverse events in nursing infants
             secondary to treatment of the mother with dasatinib and/or oxaliplatin, breastfeeding
             should be discontinued

          -  Inability to understand and sign informed consent

          -  Any other condition that in the opinion of the investigators would make the study
             therapy unsafe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne M Noonan, MBBChBAO, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Anne Noonan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

